---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-346894"
form_type: "8-K"
ticker: "RNXT"
cik: "0001574094"
company_name: "RenovoRx, Inc."
filed_at: "2026-08-12T20:16:29+00:00"
generated_at: "2026-08-12T20:18:32.565793+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# RenovoRx Q2 revenue $909K, up 115% YoY; raises FY2026 guidance to $3.75-4.25M

## Summary
- Q2 2026 revenue $909K, up 61% QoQ and 115% YoY; record quarter, 83% of FY2025 total revenue.
- FY2026 revenue guidance raised to $3.75-4.25M from $3-4M, implying ~241-286% YoY growth.
- 21 active commercial cancer centers (+30% from 16 in Q1); 63 in pipeline; Q3 revenue expected to exceed Q2.
- Phase III TIGeR-PaC fully enrolled; 78/86 events; completion H1 2027, topline H2 2027.
- First RenovoCath use in sarcoma patient; cash $9.5M, sufficient into H2 2027; break-even target Q4 2027.

## SEC filing metadata
- accession: 0001193125-26-346894
- form_type: 8-K
- ticker: RNXT
- cik: 0001574094
- company_name: RenovoRx, Inc.
- filed_at: 2026-08-12T20:16:29+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1574094/000119312526346894/0001193125-26-346894-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1574094/000119312526346894/rnxt-20260812.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-346894
- JSON: https://secwatch.observer/filing/0001193125-26-346894.json
- Plain text: https://secwatch.observer/filing/0001193125-26-346894.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.